Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C7H13NO |
| Molecular Weight | 127.1842 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1CN2CCC1CC2
InChI
InChIKey=IVLICPVPXWEGCA-UHFFFAOYSA-N
InChI=1S/C7H13NO/c9-7-5-8-3-1-6(7)2-4-8/h6-7,9H,1-5H2
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| 3-(2-Amino-1-methyl-4-oxo-4,5-dihydro-1H-imidazol-5-yl)-3-hydr-oxy-1-phenyl-indolin-2-one ethanol solvate. | 2009-09-12 |
|
| rac-2-(2-Amino-4-oxo-4,5-dihydro-1,3-thia-zol-5-yl)-2-hydroxy-indane-1,3-dione. | 2009-07-18 |
|
| Stereoselective synthesis of (R)-3-quinuclidinol through asymmetric reduction of 3-quinuclidinone with 3-quinuclidinone reductase of Rhodotorula rubra. | 2009-06 |
|
| (Z)-Methyl 4-({3-[(2,5-dioxoimidazolidin-4-yl-idene)meth-yl]-1H-indol-1-yl}meth-yl)benzoate. | 2008-12-10 |
|
| rac-(Z)-2-(2-Thienylmethylene)-1-azabicyclo[2.2.2]octan-3-ol. | 2007-08 |
|
| Aza-Morita-Baylis-Hillman reactions and cyclizations of conjugated dienes activated by sulfone, ester, and keto groups. | 2007-04-27 |
|
| Preparation of enantiomers of quinuclidin-3-Ol derivatives and their interactions with human cholinesterases. | 2005-12-15 |
|
| Morita-Baylis-Hillman reaction and cyclization of 1-(p-toluenesulfonyl)-1,3-butadiene with aldimines. | 2005-06-09 |
|
| Correlation between pK(a) and reactivity of quinuclidine-based catalysts in the Baylis-Hillman reaction: discovery of quinuclidine as optimum catalyst leading to substantial enhancement of scope. | 2003-02-07 |
|
| Capillary electrophoresis/mass spectrometry: a promising tool for the control of some physiologically hazardous compounds. I-derivatives of 3-quinuclidinol. | 2002-12 |
|
| Rate acceleration of the Baylis-Hillman reaction in polar solvents (water and formamide). Dominant role of hydrogen bonding, not hydrophobic effects, is implicated. | 2002-01-25 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
216-578-4
Created by
admin on Mon Mar 31 18:10:24 GMT 2025 , Edited by admin on Mon Mar 31 18:10:24 GMT 2025
|
PRIMARY | |||
|
7710
Created by
admin on Mon Mar 31 18:10:24 GMT 2025 , Edited by admin on Mon Mar 31 18:10:24 GMT 2025
|
PRIMARY | |||
|
3684-26-2
Created by
admin on Mon Mar 31 18:10:24 GMT 2025 , Edited by admin on Mon Mar 31 18:10:24 GMT 2025
|
SUPERSEDED | |||
|
15381
Created by
admin on Mon Mar 31 18:10:24 GMT 2025 , Edited by admin on Mon Mar 31 18:10:24 GMT 2025
|
PRIMARY | |||
|
DTXSID50862716
Created by
admin on Mon Mar 31 18:10:24 GMT 2025 , Edited by admin on Mon Mar 31 18:10:24 GMT 2025
|
PRIMARY | |||
|
m9469
Created by
admin on Mon Mar 31 18:10:24 GMT 2025 , Edited by admin on Mon Mar 31 18:10:24 GMT 2025
|
PRIMARY | Merck Index | ||
|
1619-34-7
Created by
admin on Mon Mar 31 18:10:24 GMT 2025 , Edited by admin on Mon Mar 31 18:10:24 GMT 2025
|
PRIMARY | |||
|
C474540
Created by
admin on Mon Mar 31 18:10:24 GMT 2025 , Edited by admin on Mon Mar 31 18:10:24 GMT 2025
|
PRIMARY | |||
|
93905
Created by
admin on Mon Mar 31 18:10:24 GMT 2025 , Edited by admin on Mon Mar 31 18:10:24 GMT 2025
|
PRIMARY | |||
|
974MVZ0WOK
Created by
admin on Mon Mar 31 18:10:24 GMT 2025 , Edited by admin on Mon Mar 31 18:10:24 GMT 2025
|
PRIMARY | |||
|
115239
Created by
admin on Mon Mar 31 18:10:24 GMT 2025 , Edited by admin on Mon Mar 31 18:10:24 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
